Alphatec Holdings, Inc. Names Leslie H. Cross Chairman of the Board of Directors
01 Août 2011 - 3:00PM
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of
Alphatec Spine, Inc., a medical device company that designs,
develops, manufactures and markets products for the surgical
treatment of spine disorders, with a focus on treating conditions
related to the aging spine, today announced that its Board of
Directors elected Leslie H. Cross the non-executive Chairman of the
Board of Directors.
Mr. Cross recently retired as the President and Chief Executive
Officer of DJO Global, Inc. ("DJO Global"), a position he has held
since 1995. Mr. Cross continues to serve as a Director and
Chairman of DJO Global. DJO Global is a manufacturer and
worldwide leading distributor of electrotherapy products,
orthopedic implants and orthopedic rehabilitation
products. During his tenure with DJO Global, the company's
revenues grew from approximately $30 million to $966 million, with
adjusted EBITDA in 2010 of $262 million. Mr. Cross has held
principal executive roles at DJO Global and its predecessors since
1990.
Mortimer Berkowitz III, the Chairman of the Executive Committee
of the Board of Directors, said, "I am pleased that Les Cross has
agreed to serve as the Chairman of our Board of Directors.
Les is a highly talented business leader who has repeatedly driven
growth, profitability and shareholder value in the orthopedics
industry. Having known Les for many years, we were pleased to
recruit him to join the Board of Directors earlier this year and we
believe that he will be an outstanding Chairman of the Board of
Directors."
Dirk Kuyper, Alphatec Spine's President and CEO, said "I look
forward to working closely with Les as we drive towards our goal of
being a top-5 global market leader."
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec
Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device
company that designs, develops, manufactures and markets products
for the surgical treatment of spine disorders, primarily focused on
the aging spine. The Company's mission is to combine
world-class customer service with innovative, surgeon-driven design
that will help improve the aging patient's quality of
life. The Company is poised to achieve its goal through new
solutions for patients with osteoporosis, stenosis and other aging
spine deformities, improved minimally invasive products and
techniques and integrated biologics solutions. In addition to
its U.S. operations, the Company also markets its products in over
50 international markets through its subsidiary, Scient'x S.A.S.,
via a direct salesforce in France, Italy and the United Kingdom and
via independent distributors in the rest of Europe, the Middle East
and Africa, South America and Latin America. In Asia and
Australia, the Company markets its products through its subsidiary,
Alphatec Pacific, Inc., and through Scient'x's distributors in
China, Korea and Australia.
The Alphatec Holdings, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3520
Forward Looking Statements
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainty. Such statements are
based on management's current expectations and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These forward-looking statements include, but are not
limited to: Alphatec Spine's ability to accelerate new product
momentum, bring to market differentiated products and commercialize
its product pipeline. Alphatec Spine cautions investors that there
can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such
forward-looking statements as a result of various factors,
including, but not limited to, the following: the ability of the
Chairman of the Board and the Board of Directors to affect the
Company's growth and increase shareholder value, Alphatec Spine's
ability to meet its financial guidance, the growth rate of the
spine market related to aging and elderly patients, uncertainty of
success in developing new products or products currently in
Alphatec Spine's pipeline and those products that are intended to
treat disorders prevalent in aging patients, failure to achieve
acceptance of Alphatec Spine's products by the surgeon community,
failure to obtain or maintain the right from the FDA to market and
sell products, or unexpected or prolonged delays in the process
Alphatec Spine's ability to develop and expand its business in the
United States, Asia and Europe, continuation of favorable third
party payor reimbursement for procedures performed using Alphatec
Spine's products, unanticipated expenses or liabilities or other
adverse events affecting cash flow or Alphatec Spine's ability to
successfully control its costs or achieve profitability,
uncertainty of additional funding, Alphatec Spine's ability to
compete with other competing products and with emerging new
technologies, product liability exposure, patent infringement
claims and claims related to Alphatec Spine's intellectual
property. Please refer to the risks detailed from time to time in
Alphatec Spine's SEC reports, including quarterly reports on Form
10-Q, reports on Form 8-K and annual reports on Form 10-K. Alphatec
Spine disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
CONTACT: Michael O'Neill
Chief Financial Officer
Alphatec Spine, Inc.
(760) 494-6746
investorrelations@alphatecspine.com
Westwicke Partners
Lynn C. Pieper
(415) 202-5678
lynn.pieper@westwicke.com
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024